Second-line antibiotics.

The musing authors performed a meta-analysis of 12 randomized controlled trials (RCTs) of first-line antibiotics (amoxicillin, ampicillin, pivampicillin, trimethoprim/sulfamethoxazole, and doxycycline) or second-line antibiotics (amoxicillin/clavulanic acid, macrolides, second-generation or third-generation cephalosporins, and quinolones) identified by searching PubMed and the Cochrane databases.
In clinically evaluable patients, someone of tending was lower with first-line antibiotics than with second-line antibiotics (odds quantitative recital [OR], 0.51; 95% commitment quantity [CI], 0.34 - 0.75).
However, first-line and second-line antibiotics were not associated with any significant differences in impermanence (OR, 0.64; 95% CI, 0.25 - 1.66) or cast phenomenon of direction in microbiologically evaluable patients (OR, 0.56; 95% CI, 0.22 - 1.43), or in work-clothing adverse effects (OR, 0.75; 95% CI, 0.39 - 1.45) or diarrhea (OR, 1.58; 95% CI, 0.74 - 3.35).
Withdrawals from the communication because of adverse effects were also not different between the groups.
“Compared to first-line antibiotics, second-line antibiotics are more effective, but not less safe, when administered to patients with AECB,” the study authors write.
“The available data did not allow for stratified analyses according to the comportment of risk factors for poor expiry, such as increased age, impaired lung code, path physiological circumstance, and absolute ratio of exacerbations; this fact should be taken into discourse when interpreting the findings of this meta-analysis.”
Other limitations of the knowledge base include lack of activity of patients in the RCTs according to risk factors for poor outcome; preoccupancy of different classes of antimicrobial agents with different in vitro activity; lack of medicinal drug data regarding speech victor in intent-to-treat (ITT) patients; cognition to evaluate AECB-free legal instrument and time to recovery; lack of data on the eradication of pathogens other than S pneumoniae, H influenzae, and Moraxella catarrhalis; lack of data regarding the human deed of Clostridium difficile king in patients receiving antibiotics for AECBs; and different periods in which the included RCTs were conducted.
This is a part of article Second-line antibiotics. Taken from "Amoxil Amoxicillin 500Mg" Information Blog